Prudential Financial Inc. Raises Stock Position in Inogen, Inc. (NASDAQ:INGN)

Prudential Financial Inc. raised its stake in Inogen, Inc. (NASDAQ:INGN - Free Report) by 141.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 360,002 shares of the medical technology company's stock after buying an additional 210,961 shares during the period. Prudential Financial Inc. owned about 1.51% of Inogen worth $3,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC purchased a new stake in shares of Inogen in the fourth quarter valued at approximately $43,000. Quarry LP purchased a new position in Inogen during the 3rd quarter worth $59,000. Intech Investment Management LLC bought a new stake in Inogen during the 4th quarter valued at $94,000. Ieq Capital LLC purchased a new stake in shares of Inogen in the 4th quarter worth $94,000. Finally, Verition Fund Management LLC bought a new position in shares of Inogen during the 3rd quarter worth $106,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Price Performance

NASDAQ INGN traded up $0.05 during midday trading on Monday, hitting $7.09. 734,110 shares of the company traded hands, compared to its average volume of 243,390. Inogen, Inc. has a 52 week low of $6.14 and a 52 week high of $13.33. The company's 50-day simple moving average is $8.92 and its 200-day simple moving average is $9.35. The company has a market cap of $190.63 million, a PE ratio of -3.15 and a beta of 1.48.

Analyst Ratings Changes

Several research firms recently weighed in on INGN. StockNews.com downgraded Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Inogen in a report on Wednesday, February 26th.

Remove Ads

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.